Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 13794
Country/Region: Ethiopia
Year: 2016
Main Partner: Oromia Health Bureau - Ethiopia
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $8,908,463 Additional Pipeline Funding: $480,600

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,054,964
Care: TB/HIV (HVTB) $374,033
Care: Pediatric Care and Support (PDCS) $165,198
Laboratory Infrastructure (HLAB) $156,694
Strategic Information (HVSI) $179,652
Health Systems Strengthening (OHSS) $90,076
Biomedical Prevention: Blood Safety (HMBL) $48,581
Testing: HIV Testing and Counseling (HVCT) $99,613
Sexual Prevention: Other Sexual Prevention (HVOP) $94,612
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $791,761
Treatment: Adult Treatment (HTXS) $4,903,811
Treatment: Pediatric Treatment (PDTX) $949,468
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 165
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 459
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 125
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 364
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 181
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 501
GEND_GBV Number of people receiving post-GBV care 2017 306
GEND_GBV Number of people receiving post-GBV care 2017 865
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 157,393
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 300
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 163,836
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 312
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 1,087,425
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 1,725
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 593,364
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 594
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 2,002,028
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 2,931
HTS_TST Service Delivery Point (Facility): Inpatient 2017 1,236
HTS_TST Service Delivery Point (Facility): Inpatient 2017 211
HTS_TST Service Delivery Point (Facility): Other PITC 2017 821
HTS_TST Service Delivery Point (Facility): Other PITC 2017 140
HTS_TST Service Delivery Point (Facility): Outpatient 2017 4,735
HTS_TST Service Delivery Point (Facility): Outpatient 2017 808
HTS_TST Service Delivery Point (Facility): PMTCT 2017 6,892
HTS_TST Service Delivery Point (Facility): PMTCT 2017 1,175
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 926
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 158
HTS_TST Service Delivery Point (Facility): VCT 2017 2,574
HTS_TST Service Delivery Point (Facility): VCT 2017 439
HTS_TST Sum of Aggregated Age/Sex <15 2017 321,229
HTS_TST Sum of Aggregated Age/Sex <15 2017 612
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 1,680,789
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 2,319
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 2,002,018
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 2,931
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 1,519
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 1
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 1,818
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 1
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 14,674
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 10
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 7,487
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 3
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 2,900
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2017 2,900
KP_PREV Total estimated number of key population in the catchment area 2017 22,371
KP_PREV_den By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) 2017 22,371
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 57
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 57
LAB_PT CD4: Number of laboratories that perform this testing 2017 74
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 4
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2017 4
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2017 4
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 233
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 233
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 233
LAB_PT HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 4
LAB_PT HIV viral load: Number of laboratories that participate in this PT program 2017 4
LAB_PT HIV viral load: Number of laboratories that perform this testing 2017 4
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 46
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 46
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 233
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 2
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program 2017 2
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that perform this testing 2017 2
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 4
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program 2017 4
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing 2017 32
PMTCT_ART Already on ART at beginning of current pregnancy 2017 74
PMTCT_ART Already on ART at beginning of current pregnancy 2017 1,821
PMTCT_ART New on ART 2017 45
PMTCT_ART New on ART 2017 1,559
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 8,257
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 474,996
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 80
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 2,614
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 20
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 668
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 1
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 22
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 2
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 58
PMTCT_EID Sum of Infant Age disaggregates 2017 100
PMTCT_EID Sum of Infant Age disaggregates 2017 3,282
PMTCT_STAT By: Known positives at entry 2017 69
PMTCT_STAT By: Known positives at entry 2017 1,917
PMTCT_STAT By: Number of new positives identified 2017 39
PMTCT_STAT By: Number of new positives identified 2017 1,602
PMTCT_STAT Number of new ANC and L&D clients 2017 8,773
PMTCT_STAT Number of new ANC and L&D clients 2017 513,949
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 8,257
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 474,996
PMTCT_STAT Sum of Positives Status disaggregates 2017 3,519
PMTCT_STAT Sum of Positives Status disaggregates 2017 108
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 25,923
PP_PREV Total number of people in the target population 2017 31,119
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 62
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 550
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 89
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 738
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 1,450
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 1,239
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 7,897
TB_SCREENDX [Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 31
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) 2017 9
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 2,371
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only 2017 9
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 2,376
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 13
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 4,013
TB_SCREENDX Screen Result: Screened Positive for TB 2017 11,269
TB_SCREENDX Screen Results: Screened Positive for TB 2017 44
TB_SCREENDX Screened for TB by Age/Sex: <15 Female 2017 18
TB_SCREENDX Screened for TB by Age/Sex: <15 Male 2017 20
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 255
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 63,268
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 142
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 39,036
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 4,998
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 5,316
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 435
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 112,622
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 916
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 5,887
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,240
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 7,436
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 15,277
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 16,404
TX_CURR Aggregated Age/Sex: <15 Female 2017 21
TX_CURR Aggregated Age/Sex: <15 Female 2017 5,314
TX_CURR Aggregated Age/Sex: <15 Male 2017 22
TX_CURR Aggregated Age/Sex: <15 Male 2017 5,667
TX_CURR Aggregated Age/Sex: 15+ Female 2017 293
TX_CURR Aggregated Age/Sex: 15+ Female 2017 67,783
TX_CURR Aggregated Age/Sex: 15+ Male 2017 164
TX_CURR Aggregated Age/Sex: 15+ Male 2017 41,851
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 500
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 120,721
TX_CURR Sum of Aggregated Age/Sex <15 2017 43
TX_CURR Sum of Aggregated Age/Sex <15 2017 10,981
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 457
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 109,634
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 500
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 120,615
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 2
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 1,801
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 2
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 2,109
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 26
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 14,114
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 14
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 7,833
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 59
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 25,878
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 44
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 25,857
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 62
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 76,467
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 49
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 61,179
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 2
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 2,727
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 2
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 2,890
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 29
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 34,361
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 16
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 21,214
TX_PVLS Numerator: Indication: Routine 2017 40
TX_PVLS Numerator: Indication: Routine 2017 48,944
TX_PVLS Numerator: Indication: Targeted 2017 9
TX_PVLS Numerator: Indication: Targeted 2017 12,235
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 3
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 3,378
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 3
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 3,597
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 37
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 42,960
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 19
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 26,535
TX_PVLS_den Denominator: Indication: Routine 2017 49
TX_PVLS_den Denominator: Indication: Routine 2017 61,187
TX_PVLS_den Denominator: Indication: Targeted 2017 13
TX_PVLS_den Denominator: Indication: Targeted 2017 15,282
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 412
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 524
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4,732
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,573
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 9
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 8,354
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 11
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 9,364
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 16
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 457
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 539
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 5
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 5,285
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 8
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,906
Cross Cutting Budget Categories and Known Amounts Total: $2,691,990
Food and Nutrition: Policy, Tools, and Service Delivery $137,145
Renovation $1,791,000
Motor Vehicles: Purchased $400,000
Key Populations: Sex Workers $55,845
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Monitoring and evaluation of SW programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: Gender Based Violence (GBV) $308,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation